Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Blood (2025) 146 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2025-LBA-6

Published: 2025

Journal Articles

Comparative analysis of toxicity and efficacy of melphalan at doses of 140 mg/m2 VS. 200 mg/m2 as a conditioning regimen prior to autologous stem cell transplantation.

Beatriz Chiclana-Rodríguez, Marta García Culebras, Patricia Alcalde-Mellado, Nancy Rodriguez-Torres, Lucía Mezquita Romero, Juan Luis Reguera, Javier Camuña Correa, Estrella Carrillo-Cruz, Marta Reinoso -Segura, Eusebio Martín Chacón, Laura Pérez Ortega, Jose Francisco Falantes, Cristina Blazquez Go I, Francisco Manuel Martin-Dominguez, Maria Eva Mingot, Virginia Escamilla Gomez, José Antonio Pérez-Simón

Blood (2025) 146 (Supplement 1): 4061.

https://doi.org/10.1182/blood-2025-4061

Published: 2025

Journal Articles

Talquetamab outcomes from practice outside of clinical trials: The bital study

María-Victoria Mateos, Marcos Lorenzo Perez, Ana Saus Carreres, Mario Arnao, Elena Fernández Poveda, Ana Pilar Gonzalez, Sunil Lakhwani, Juan Luis Reguera, Jose Maria Sanchez Pina, Ana Sánchez Quintana, Miriam Concepcion Gonzalez Pardo, María-Jesús Blanchard, Paula Rodriguez-Otero

Blood (2025) 146 (Supplement 1): 5827.

https://doi.org/10.1182/blood-2025-5827

Published: 2025

Journal Articles

Early intervention for cytokine release syndrome after chimeric antigen receptor T-cell therapy is associated with an increased risk of cytopenias and infections in patients with large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 1944.

https://doi.org/10.1182/blood-2025-1944

Published: 2025

Journal Articles

Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing

María-Jesús Blanchard, Marcos Lorenzo Perez, Ana Saus Carreres, Mario Arnao, Elena Fernández Poveda, Ana Pilar Gonzalez, Sunil Lakhwani, Juan Luis Reguera, Jose Maria Sanchez Pina, Ana Sánchez Quintana, Miriam Concepcion Gonzalez Pardo, María-Victoria Mateos, Paula Rodriguez-Otero

Blood (2025) 146 (Supplement 1): 2272.

https://doi.org/10.1182/blood-2025-2272

Published: 2025

Journal Articles

The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data

Blood (2025) 146 (Supplement 1): 135.

https://doi.org/10.1182/blood-2025-135

Published: 2025

Journal Articles

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL

Blood (2025) 146 (Supplement 1): 467.

https://doi.org/10.1182/blood-2025-467

Published: 2025

Journal Articles

Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety Outcomes for Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for the Treatment of Third-Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Alexander P. Boardman, Juan Luis Reguera, Paul Spin, Pearl Wang, Lamees Almuallem, Jenna Ellis, Jamie Zheng, Jinender Kumar, Thalia Farazi, Alejandro Martín García-Sancho, Koji Izutsu

Blood (2024) 144 (Supplement 1): 3028.

https://doi.org/10.1182/blood-2024-197948

Published: 2024

Journal Articles

Consolidative Allogenic Hematopoietic Cell Transplantation Vs. Watch and Wait Strategy for B-Cell Acute Lymphoblastic Leukemia Patients with Early Loss of B-Cell Aplasia after Chimeric Antigen Receptor T-Cell Therapy

Sergi Camarillas, Anna Alonso-Saladrigues, Agueda Molinos Quintana, Víctor Navarro, Blanca Herrero-Velasco, Mario Sánchez-Salinas, Berta González-Martínez, Ana Africa Martin Lopez, Anna Torrent, Julia Marsal, Juan Luis Reguera, Gloria Iacoboni, Antonio Pérez-Martínez, Susana Rives, Pere Barba

Blood (2024) 144 (Supplement 1): 5898.

https://doi.org/10.1182/blood-2024-205932

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Blood (2024) 144 (Supplement 1): 4387.

https://doi.org/10.1182/blood-2024-198509

Published: 2024

Journal Articles

Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients

Blood (2024) 144 (Supplement 1): 471.

https://doi.org/10.1182/blood-2024-205809

Published: 2024

Journal Articles

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 602.

https://doi.org/10.1182/blood-2023-179474

Published: 2023

Journal Articles

ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1026.

https://doi.org/10.1182/blood-2023-180828

Published: 2023

Journal Articles

Patient-Reported Outcomes (PROs) from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL)

Guillaume Cartron, Alejandro Martin Garcia-Sancho, Juan Luis Reguera, Saurabh Dahiya, Shien Guo, Ling Shi, Laurie Eliason, Jinender Kumar, Thalia Farazi, Omotayo Fasan, Koji Izutsu

Blood (2023) 142 (Supplement 1): 668.

https://doi.org/10.1182/blood-2023-180175

Published: 2023

Journal Articles

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Blood (2023) 142 (Supplement 1): 227.

https://doi.org/10.1182/blood-2023-184942

Published: 2023

Journal Articles

Impact of Patient Selection and Management over Different Time Periods on the Outcome of Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Blood (2023) 142 (Supplement 1): 267.

https://doi.org/10.1182/blood-2023-186388

Published: 2023

Journal Articles

Longitudinal Transcriptomic Analysis of CAR-T Cells at Single-Cell Level Allows the Identification of Molecular Mechanisms Promoting Long-Term CAR-T Cell Persistence in MM

Blood (2023) 142 (Supplement 1): 2069.

https://doi.org/10.1182/blood-2023-182933

Published: 2023

Journal Articles

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Blood (2023) 142 (Supplement 1): 4883.

https://doi.org/10.1182/blood-2023-185858

Published: 2023

Journal Articles

New Optimized Academic Anti-BCMA CAR (CARTemis-1): How Does the Manufacturing Process Impact CAR-T Cell Features?

Belén Sierro-Martínez, Virginia Escamilla Gomez, Laura Perez-Ortega, Beatriz Guijarro-Albaladejo, Paola Hernández-Díaz, María de la Rosa-Garrido, Maribel Lara-Chica, Juan Luis Reguera, Luzalba Sanoja Flores, Blanca Arribas-Arribas, Miguel-Ángel Montiel-Aguilera, Gloria Carmona, Maria-Jose Robles, Teresa Caballero, Javier Briones, Hermann Einsele, Michael Hudecek, Jose A. Pérez-Simón, Estefania Garcia-Guerrero

Blood (2023) 142 (Supplement 1): 6866.

https://doi.org/10.1182/blood-2023-186095

Published: 2023

Journal Articles

Is CAR T a Drug or a Therapeutic Pathway? Systematic Review, (Re-)Estimation of Efficacy Endpoints and Metanalyses in Large B-Cell Lymphoma Real World Reports

Blood (2023) 142 (Supplement 1): 6938.

https://doi.org/10.1182/blood-2023-178526

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Comparative analysis of toxicity and efficacy of melphalan at doses of 140 mg/m2 VS. 200 mg/m2 as a conditioning regimen prior to autologous stem cell transplantation.

Talquetamab outcomes from practice outside of clinical trials: The bital study

Early intervention for cytokine release syndrome after chimeric antigen receptor T-cell therapy is associated with an increased risk of cytopenias and infections in patients with large B-cell lymphoma

Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing

The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL

Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety Outcomes for Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for the Treatment of Third-Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Consolidative Allogenic Hematopoietic Cell Transplantation Vs. Watch and Wait Strategy for B-Cell Acute Lymphoblastic Leukemia Patients with Early Loss of B-Cell Aplasia after Chimeric Antigen Receptor T-Cell Therapy

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma

Patient-Reported Outcomes (PROs) from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL)

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Impact of Patient Selection and Management over Different Time Periods on the Outcome of Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Longitudinal Transcriptomic Analysis of CAR-T Cells at Single-Cell Level Allows the Identification of Molecular Mechanisms Promoting Long-Term CAR-T Cell Persistence in MM

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

New Optimized Academic Anti-BCMA CAR (CARTemis-1): How Does the Manufacturing Process Impact CAR-T Cell Features?

Is CAR T a Drug or a Therapeutic Pathway? Systematic Review, (Re-)Estimation of Efficacy Endpoints and Metanalyses in Large B-Cell Lymphoma Real World Reports

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only